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Crunch time for funding of universal access to
antiretroviral treatment for people with HIV
infection
Progress in rolling back HIV
The seemingly inexorable rise in global HIV
incidence during the ﬁrst 30 years of the epidemic
peaked towards the end of the 1990s. However,
global HIV prevalence and deaths still remain at
crisis levels, with 33.4 million people living with HIV
and 2 million deaths in 2008 (1). The region most
severely affected is sub-Saharan Africa, with 67% of
HIV infections and 72% of HIV-related deaths
worldwide in 2008 (1). Changing the course of an
epidemic of a primarily sexually transmitted infec-
tion by changing sexual behaviour is difﬁcult – ‘king
sex is an unruly monarch’. Demonstrating effective-
ness and impact of behaviour change interventions
has been difﬁcult and there is little agreement on
which speciﬁc interventions most
effectively change behaviour. Male
circumcision is one of few inter-
ventions shown in randomised tri-
als to be effective in decreasing
HIV transmission risk (2–4), but
programmatic delivery is limited
and long-term results are awaited.
Thirty years’ advances in HIV
virology and immunology have
been a tremendous scientiﬁc suc-
cess, but have not yet resulted in
widely available HIV prevention
technologies. The high variability
of HIV envelope glycoproteins has
frustrated attempts to develop an
effective vaccine. After nearly
2 decades of research which failed
to ﬁnd an effective vaginal micro-
bicide (5), the recent ﬁnding that
tenofovir gel decreases risk of HIV
acquisition by 39% is promising
(6). Scientiﬁc advances have, how-
ever, resulted in widely applied
HIV diagnosis and treatment tech-
nologies. Diagnostic HIV tests are
widely available, rapid, easy-to-use,
accurate and relatively cheap.
Antiretroviral (ARV) drugs can
effectively contain HIV even if a
cure is not yet possible. Prolongation of life by ART
– a tribute to science and technology – has trans-
formed the previously bleak outlook for people with
HIV infection. The impact of improved ART access
on HIV-related mortality at the population level has
been shown in countries with high income, e.g. UK
(7) and low income, e.g. Malawi (8).
Progress towards universal ART access
The 10-fold expansion in access to ART in low- and
middle-income countries over the 5 years up to 2007
is a tremendous achievement (9). However, the
uphill task is not even half completed. The ﬁve mil-
lion adults and children with HIV infection in low-
and middle-income countries receiving ART by the
end of 2009 represented only 36% of those in need
The HIV epidemic is a leading global health challenge. While
controversy has surrounded the best HIV prevention strategy,
remarkable consensus has supported the campaign for
universal access to antiretroviral therapy (ART) for people
with HIV infection. As a necessary humane response to the
epidemic, the moral imperative to provide ART to people
with HIV infection has struck a chord of global solidarity.
Much of the funding mobilised for the global response to HIV
has supported successful expansion in ART access. Funding is
now at a critical juncture as the global ﬁnancial crisis bites
and funders hesitate. Providing universal ART access is a
steep hill only half climbed – faltering at this point risks rapid
loss of recent gains, and the need to begin again an even
steeper climb in future just to regain our current incomplete
and perilous position. Against the background of overall
efforts to roll back the HIV epidemic, we consider the
implications of faltering ﬁnances for universal ART access and
argue for additional funding, used efﬁciently. Progress
towards universal ART access has individual and also
potential community beneﬁts. Although we focus mainly on
sub-Saharan Africa as the region most badly affected by HIV
and with the least resources to respond, other regions face
similar issues.
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The
tremendous
progress in
expanding
global access
to antiretro-
viral treatment
for people
with HIV
infection is
threatened by
faltering
funding
commitments(based on 2010 WHO guidelines) (9). This progress
demonstrates proof of principle – that with political
and ﬁnancial commitment universal access to ART is
possible – but an unﬁnished agenda remains.
The impact of faltering ﬁnances on
ART access
Faltering political and ﬁnancial commitment threat-
ens to stall progress towards universal ART access.
Starting in 2008 the shock waves of the global ﬁnan-
cial crisis emanated quickly from the USA around
the world. The myriad effects of the crisis include
threats in developing countries to health services,
including ART provision (much of which is funded
by donors). The health infrastructure which has been
painstakingly built up for ART provision can be eas-
ily dismantled in a funding downturn.
Developed nations have responded to the ‘credit
crunch’ and the collapse of banking systems by allo-
cating vast national resources to bail out ﬁnancial
institutions and industries while their economies
contract. Under domestic pressure to curb spending,
donor governments are cutting back on development
assistance, which may account for a signiﬁcant pro-
portion of health service expenditure in developing
countries. Developing country governments under
ﬁscal constraint may also squeeze health sector
expenditure. The global economic downturn there-
fore compounds the problems of diseases of poverty
(e.g. HIV, tuberculosis and malaria) by a double
whammy – as socioeconomic conditions which
favour the spread of these diseases deteriorate, funds
for the health sector response are restricted (10).
After substantial yearly increases since 2002 in
support for ART access, the USA and other donors
have stalled in their funding commitments, with dis-
bursements decreased for 2009 (11). Already by 2009
UNAIDS reported an adverse effect of the economic
crisis on ART programmes (12). The Global Fund
replenishment pledges for 2011–2013 reached $11.7
billion, far short of the $20 billion needed to expand
programmes and even short of the $13 billion
needed to keep existing programmes running (13).
Although the latest WHO guidelines recommend a
CD4 cell count of 350 cells⁄ll as a starting threshold
for ART (14), many centres in Africa continue to use
a threshold of 200 CD4 cells⁄ll because of insufﬁ-
cient ARV supply (15). Medecins sans Frontieres
have reported ART rationing to the sickest patients
in developing countries, directly contradicting the
evidence of beneﬁts of earlier treatment and WHO
guidelines (16). Consequences of failure to maintain
even the existing ARV drug supply include: more
HIV-related diseases and deaths that could have been
prevented; without treatment people becoming more
infectious, with increased risk of transmission; and
increased drug resistance generated by treatment
interruption, necessitating more expensive second-
line therapies to prevent HIV progression. Financially
squeezed ART programmes may further compromise
the quality of ART provision in Africa, where mor-
tality is high in the ﬁrst year of ART because of
health systems delays in ART initiation and the qual-
ity of care (17).
The beneﬁts of additional investment
towards universal ART access
The funds invested in achieving the current level of
ART access are a platform for further progress. Addi-
tional investment in progress towards universal ART
access beneﬁts people with HIV infection, and also
potentially the community through improved HIV
prevention and improved health systems. Early ART
initiation improves patient outcomes and also reduces
HIV infectiousness (18) and transmission (19,20),
with the potential for ‘treatment as prevention’ (21).
Early ART with cessation of viral replication and sub-
sequent immune restoration has beneﬁts for the indi-
vidual (less risk of HIV-related disease) and also
potentially for public health (improved HIV preven-
tion) and for society (increased productivity and
decreased costs of HIV-related care) (22). The strategy
of universal voluntary testing with immediate ART,
which in a mathematical model could eliminate HIV
transmission (23), needs evaluation in practice (24).
Achieving universal ART access is easier if HIV
incidence decreases. This is urgent as the rate of new
HIV infections is greater than the rate that people
with HIV start ART. Additional investments in
implementing combined prevention interventions
will decrease HIV incidence, thus facilitating ART
provision. Progress towards universal and early ART
access could become a virtuous cycle, as the more
(and the earlier) that people start ART, the greater is
the potential impact in decreasing transmission, with
fewer incident cases and fewer people needing ART.
Progress in ART provision requires investment in
strengthened health systems as well as in the health
system elements most directly involved in ART pro-
vision. The reasons why HIV has had a much greater
impact in Africa than other regions include deﬁcien-
cies in the region’s health systems. Such deﬁciencies
lead to failure to recognise emerging health prob-
lems, diagnose cases, provide quality care, manage
surveillance, promote a safe healthcare environment
and gain public conﬁdence. Lack of preparedness
increases vulnerability to future emerging health
problems, unless health systems are strengthened
T h ec h o i c ei s
stark – to build
on progress by
mobilising the
necessary
funds and
implementing
efﬁciency
measures or to
risk unra-
velling the
progress made
so far and
embracing the
consequences
of failure
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while strengthening health systems is a win-win situ-
ation for people with HIV infection and the commu-
nity.
Using funds efﬁciently
Additional funding generated for improved ART
access must be used more efﬁciently (25). In devel-
oping countries, a built-in cost-efﬁciency is that ARV
drug costs fall as coverage increases. Proposals for
maximising cost-efﬁciencies include a cross-cutting
agenda for global health to meet the challenges of
the ﬁnancial crisis (26). Disease-speciﬁc health initia-
tives and funding programmes should agree on a
cross-cutting agenda to reform the global health
architecture and maximise cost-efﬁciencies, instead
of advocating and competing for their own stake in
the limited and diminishing pool of donor funds. At
country level, greater integration of HIV and other
programme activities, e.g. tuberculosis, could
improve efﬁciency and strengthen health systems
(27). Scaling-up home-based ART (28) and clinically
driven rather than routine laboratory monitoring of
ART side-effects (29) can improve ART programme
efﬁciency. ‘How to do more with less’ is a research
priority for extending ART access in low-resource
settings (30). Finding efﬁciencies in healthcare deliv-
ery is important but does not replace sufﬁcient, pre-
dictable ﬁnancing by donors and domestic funding
from low- and middle-income countries.
Measures to ensure the lowest possible ARV drug
prices facilitate cost-efﬁciencies. Changes in wealthy
nations’ trade policies are urgently needed to avoid
creating new barriers for generic drugs. Generic com-
petition has been critical to lowering drug costs and
will be critical to also lower the prices of newer
drugs needed for long-term survival (31). The free
trade agreement with India pursued by the European
Union, for example, will further increase monopoly
protection, although India has already changed its
patent law in compliance with World Trade Organi-
zation agreements (32). Donor countries’ support for
policies to contain ARV drug costs should comple-
ment their commitment to fund ART provision.
Conclusion
Achieving universal access to ART is an uphill task
but feasible if funding is increased and used efﬁ-
ciently. The choice is stark – to build on progress or
to embrace defeat and consign the global movement
for universal access to the fate of Sisyphus (33).
Note: The views expressed by Dermot Maher are
not necessarily those of the Medical Research Coun-
cil (UK).
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